IgD myeloma is a rare subset of multiple myeloma characterized by the production of monoclonal IgD protein. This subset of myeloma generally has a more severe and aggressive clinical course. The case reported here is of a 61-year-old female with recurrent disease complicated by encephalopathy, myalgia, and extensive skeletal involvement. The bone marrow showed sheets of plasma cells and plasmablasts, with flow cytometry demonstrating a monoclonal population of CD138-positive, lambda-restricted cells. FISH demonstrated a t(11;14)(q13;q32) translocation and a gain of 1q. Despite treatments with daratumumab, bortezomib, lenalidomide, dexamethasone, and autologous stem cell transplant, the patient ultimately expired from streptococcal pneumonia with hypoxic respiratory and subsequent multiorgan failure.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Relapsing IgD Myeloma with Increased Circulating Plasma Cells: Clinical Case Report and Literature Review.
J Assoc Genet Technol
January 2025
Stony Brook University Hospital, Stony Brook, NY 11794.
IgD myeloma is a rare subset of multiple myeloma characterized by the production of monoclonal IgD protein. This subset of myeloma generally has a more severe and aggressive clinical course. The case reported here is of a 61-year-old female with recurrent disease complicated by encephalopathy, myalgia, and extensive skeletal involvement.
View Article and Find Full Text PDFAbstract： Introduction: Many reports indicate that the occurrence of multiple myeloma (MM) is closely related to inflammation and immunity. Although the survival rates have been gradually improving in recent years, the cure rate is still not optimistic enough. Therefore, it is necessary to continue exploring the causes of MM.
View Article and Find Full Text PDFDiagnostic d'un myélome multiple à immunoglobuline D Lambda avec une atteinte rénale sévère 10 ans après un plasmocytome solitaire : Un cas clinique et revue de la littérature.
Tunis Med
January 2025
Department of Nephrology, Dialysis, and Transplantation, Hedi Chaker University Hospital, Sfax, Tunisia.
Introduction: Immunoglobulin D (IgD) myeloma is a rare subtype often described as aggressive with advanced disease at diagnosis. Primary renal involvement is seen in scarce cases.
Observation: This case features a 55-year-old man with IgD lambda myeloma presenting severe renal failure at diagnosis.
[BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments.
View Article and Find Full Text PDFChange in hair texture with the use of pomalidomide for multiple myeloma: From straight to curly phenotype.
J Oncol Pharm Pract
November 2024
Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
Introduction: Pomalidomide is used for treating multiple myeloma in patients who have relapsed after prior treatment with lenalidomide and a proteasome inhibitor. Common side effects include mild cytopenias, and deep vein thrombosis. While papulo-erythematous rash has been described, hair effects are rare with this class of agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!